Erectile Dysfunction
Conditions
Brief summary
Adult subjects with mild to moderate and moderate ED who meet the study eligibility criteria will be enrolled in the study. The enrolled subjects will be randomized by a 1:1 ratio to receive the Active or Sham VERTICA® treatment. Baseline assessments will include collection of demographic data, medical history, concomitant medications and baseline clinical examinations. The initial treatment session will be performed in a clinical setting simulating home use to determine proper device use and to evaluate device tolerability, followed by continued home use of the device for a total of 6 months. Patients will be instructed to attempt sexual activity periodically over the course of the study. Every time a sexual intercourse is attempted, the patient will be requested to complete an event log using validated assessments. Patients will present for monthly follow-up visits, during which safety will be evaluated and additional efficacy assessments will be performed.
Interventions
DEVICEVERTICA Active device
VERTICA device with a therapeutic RF energy level
DEVICEVERTICA Sham device
VERTICA device with a low, non-therapeutic RF energy level
Sponsors
OHH-MED Medical Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
Study personnel, including the investigator and raters and study subjects will be blinded to the treatment assignment (active vs. sham)
Intervention model description
Active vs. Sham
Eligibility
Sex/Gender
MALE
Age
22 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* Adult, heterosexual, males between 22 and 85 years of age * Subjects diagnosed with organic ED for at least 3 months, according to the American Urology Association (AUA) Guideline Statement 1 (as described in Section 8.1.1 of the study protocol). * Subjects with an IIEF-EF score between 11-21 * Steady relationship for at least 3 months * Subject is sexually active, with at least weekly sexual intercourse attempts or 6 times a month * Subject is willing to sign informed consent and follow study protocol procedures * Subject has a smartphone
Exclusion criteria
* Castrate and late onset hypogonadism * History of Priapism or Peyronie's Disease * Surgery or radiotherapy of the pelvic region * Anatomic penile deformations or penile prosthesis * Treatment with antiandrogens * Previous whole gland treatment of the prostate (Cryoablation, HIFU, external beam radiation of seed implantation, Radical prostatectomy any approach, etc.) * History of urothelial or colorectal cancer * Major neurological conditions such as Alzheimer's, Parkinson, Multiple sclerosis, ALS, spinal cord injury, pelvic neuropathy * Evidence of neurogenic bladder or an indwelling Foley catheter or clean intermittent catheterization (CIC) within 30 days * Subjects who are taking anticoagulation or anti-platelet therapy * History of psychiatric disorders, premature ejaculation and drug or alcohol abuse * Subjects who are incarcerated * Subjects who are cognitively challenged * Serious heart or lung disease * Pregnant partner
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| A significant difference in the mean change from baseline in the International Index of Erectile Function - Erectile Function domain (IIEF-EF) scores at 12 weeks, between the treatment groups. | 12 weeks | The IIEF-EF total score ranges between 6 to 30. A higher total score indicates relatively better erectile functioning. |
| A significant change from baseline in the mean International Index of Erectile Function - Erectile Function domain (IIEF-EF) scores at 12 weeks, within the VERTICA Active treatment group. | 12 weeks | The IIEF-EF total score ranges between 6 to 30. A higher total score indicates relatively better erectile functioning. |
Countries
United States
Outcome results
None listed